* Kodiak Sciences Inc KOD.OQ reported a quarterly adjusted
loss
of 82 cents per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-1.35. The mean expectation of six analysts for the quarter
was for a loss of $1.07 per share. Wall Street expected
results to range from $-1.25 to -88 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kodiak Sciences Inc's reported EPS for the quarter was a
loss
of 82 cents.
* The company reported a quarterly loss of $43.04 million.
* Kodiak Sciences Inc shares had fallen by 27.0% this
quarter and
gained 26.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 20%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and 3 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Kodiak Sciences
Inc is $4.00
This summary was machine generated from LSEG data May 15 at
09:03 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.07 -0.82 Beat
Dec. 31 2023 -0.77 -1.13 Missed
Sep. 30 2023 -1.21 -0.95 Beat
Jun. 30 2023 -1.14 -1.53 Missed